A study worth remembering. Pts with FM-PsA had statistically higher PsA dz activity in subjective measures ONLY, not in objective measures. Make sure you take time to fully treat your patients and give them tools for FM as well as PsA. #EULAR2020 @RheumNow #AB0731 https://t.co/e3JkEmq3EZ

SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No new safety signals were identified. Check out abstract #OP0223 for the MDA/ACR50/ACR70 responses. #EULAR2020 @RheumNow https://t.co/UAx2tkKSZI

#EULAR2020 press conference report: Global Rheum Alliance for COVID19 and Eular registries provide reassurance to rheums and pts regarding immunosuppression and COVID19. The compiled data from over 600 pts in 40 countries. @RheumNow https://t.co/qMwGJTL041

• http://ow.ly/VUwb50zXWgj

Do you use different medications for different PsA domains? Teach me how you practice! #EULAR2020 @RheumNow

Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6

• E-CONGRESS

Interestingly, first line use was the only predictor of improved retention of SEC in axSpA patients in this French study. Poster #THU0386 #EULAR2020 @RheumNow https://t.co/keI9xGWKCL https://t.co/avLtJzaEOc

• E-CONGRESS

Obesity is a strong predictor of worse clinical course and treatment response in AS. Poster #THU0389 #EULAR2020 @RheumNow https://t.co/Zb2RrqSIaK https://t.co/2z1HMQ3b5G

• E-CONGRESS

This Turkish study found that obesity did NOT play a roll in tx efficacy/retention using SEC in axSpA patients. #EULAR2020 Poster #THU0390 @RheumNow https://t.co/z3imYNuxYq https://t.co/sGz9cohH6T

• E-CONGRESS

Do you routinely discuss obesity with your rheum patients? #EULAR2020 @RheumNow

nr-axSpA pts with active inflammation improved with IXE. Drug efficacy did not change in pts with elevated CRP or sacroiliitis or both. #EULAR2020 @RheumNow poster #THU0395 https://t.co/ap6Wy2eNBL https://t.co/zLoNHuSVV5

• E-CONGRESS

COAST-V and COAST-X trial results: Both TNFi experienced and naive AS pts had better work productivity compared to PBO. #EULAR2020 @RheumNow poster #THU0396 https://t.co/UPDpLqCSkG https://t.co/UTLzxxTG8K

• E-CONGRESS

SEC shows improvement in both tender and swollen peripheral joints in AS pts. #EULAR2020 @RheumNow poster #THU0397 https://t.co/M0D6Ruh8ta https://t.co/kuShSUhXbf

• E-CONGRESS

Thoughts on the #EULAR2020 e-congress? As a life long learner, I’ve enjoyed being able to attend but I miss my interactions with colleagues @RheumNow

Interesting abstract #ABO113, out of Germany found that H. Pylori ab p66-UreB, p29-UreA, and p54-flagelin are more prominent in PsA/PsO pts. Another suggested potential link to the gut microbiome and dz? Hopefully, more data to come. #EULAR2020 @RheumNow https://t.co/mQRhsmgsHw

• EULAR Abstract Archive

This UK study to determine neutrophil function in PsA found that SEC does not affect neutrophil host defense. Check out #ABO115 for further details. An interesting find w/ regard to the inflammatory blockade and mediators of dz. #EULAR2020 @RheumNow https://t.co/EwLdlKU06A

• EULAR Abstract Archive